Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dyne Therapeutics Inc DYN

Healthcare Biotechnology
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.


NDAQ:DYN - Post by User

Dyne Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson May 20, 2024 12:30pm
45 Views
Post# 36048772

Buy Recommendation Issued On DYN By H.C. Wainwright

Buy Recommendation Issued On DYN By H.C. Wainwright
Just In: $DYN Buy Recommendation Issued On DYN By H.C. Wainwright2024-05-20 11:30:02 ET H.C. Wainwright analyst issues BUY recommendation for DYN on May 20, 2024 09:31AM ET. The previous analyst recommendation was Buy. DYN was trading at $34.3919 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...DYN - Buy Recommendation Issued On DYN By H.C. Wainwright

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities